ArticleBMC nephrology2026
Association of urinary post-translationally modified fetuin-a and outcomes in acute kidney disease.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRisk stratification during the acute kidney disease period remains suboptimal with existing staging systems.
methodsWe used prospectively collected clinical data and samples from 130 patients with acute kidney disease to evaluate the association between a novel biomarker, urinary post-translationally modified fetuin-A (uPTM-FetA), and clinical outcomes. Traditional staging systems based on the serum creatinine ratio, estimated glomerular filtration rate, or albuminuria were also compared. The outcome of interest was death or dialysis within 180 days.
resultsThe level of uPTM-FetA was significantly associated with the outcome in both logistic regression (odds ratio 3.41, 95% confidence interval 1.35-8.62, P = 0.01) and Cox models (hazard ratio 2.91, 95% confidence interval 1.30-6.51, P = 0.009). The crude area under the receiver operating characteristic curve was 0.75. Grouping with tertiles of uPTM-FetA levels showed discrimination between patients with and without the outcome. Furthermore, integrating uPTM-FetA into the traditional staging system of acute kidney disease was associated with improvement in model fit, risk classification, and clinical utility.
conclusionsuPTM-FetA during the acute kidney disease period offers the potential to provide additional prognostic information. Given the small sample size, the results should be viewed as exploratory. Future studies with independent cohorts are warranted to validate this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.